FDA Approves First Drug To Improve Symptoms In Children With Rare Inherited Heart Condition

By Reuters News

- FDA:

  • FDA APPROVES FIRST DRUG TO IMPROVE FUNCTIONAL CAPACITY AND SYMPTOMS IN CHILDREN WITH RARE INHERITED HEART CONDITION

  • FDA: APPROVED CAMZYOS (MAVACAMTEN) CAPSULES AS FIRST TREATMENT FOR CHILDREN WITH SYMPTOMATIC OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY - WEBSITE

  • FDA: CAMZYOS CARRIES BOXED WARNING FOR HEART FAILURE RISK, RESTRICTED TO REMS PROGRAM

Further company coverage: BMY.N

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk